- Home
- PETZ vs ABP Comparison
PETZ vs ABP Comparison
Compare PETZ & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | ABP |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.5M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | PETZ | ABP |
|---|---|---|
| Price | $1.11 | $1.91 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.5K | ★ 31.2K |
| Earning Date | 11-13-2025 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,046,006.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $0.65 | $1.94 |
| 52 Week High | $1.68 | $36.00 |
Technical Indicators
Market Signals| Indicator | PETZ | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 69.39 | 26.48 |
| Support Level | $1.04 | $2.00 |
| Resistance Level | $1.20 | $2.90 |
| Average True Range (ATR) | 0.08 | 0.40 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 98.24 | 7.35 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.